GW&K Investment Management LLC Lowers Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

GW&K Investment Management LLC decreased its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 0.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 511,356 shares of the company's stock after selling 2,726 shares during the period. GW&K Investment Management LLC owned about 0.52% of Neurocrine Biosciences worth $56,556,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. OneDigital Investment Advisors LLC raised its holdings in Neurocrine Biosciences by 2.1% during the fourth quarter. OneDigital Investment Advisors LLC now owns 4,215 shares of the company's stock worth $575,000 after purchasing an additional 87 shares in the last quarter. HighPoint Advisor Group LLC grew its stake in Neurocrine Biosciences by 4.1% in the 4th quarter. HighPoint Advisor Group LLC now owns 2,446 shares of the company's stock worth $334,000 after acquiring an additional 96 shares during the period. Huntington National Bank grew its stake in Neurocrine Biosciences by 73.5% in the 4th quarter. Huntington National Bank now owns 229 shares of the company's stock worth $31,000 after acquiring an additional 97 shares during the period. Utah Retirement Systems grew its stake in Neurocrine Biosciences by 0.6% in the 4th quarter. Utah Retirement Systems now owns 16,583 shares of the company's stock worth $2,264,000 after acquiring an additional 100 shares during the period. Finally, GeoWealth Management LLC grew its stake in Neurocrine Biosciences by 65.4% in the 4th quarter. GeoWealth Management LLC now owns 258 shares of the company's stock worth $35,000 after acquiring an additional 102 shares during the period. Institutional investors and hedge funds own 92.59% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on NBIX. The Goldman Sachs Group began coverage on shares of Neurocrine Biosciences in a research note on Thursday, July 10th. They set a "buy" rating and a $182.00 price objective for the company. JPMorgan Chase & Co. boosted their price objective on shares of Neurocrine Biosciences from $183.00 to $184.00 and gave the stock an "overweight" rating in a report on Wednesday, March 26th. Evercore ISI cut their price objective on shares of Neurocrine Biosciences from $190.00 to $185.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. UBS Group boosted their price objective on shares of Neurocrine Biosciences from $152.00 to $174.00 and gave the stock a "buy" rating in a report on Wednesday, July 9th. Finally, HC Wainwright cut their price objective on shares of Neurocrine Biosciences from $185.00 to $168.00 and set a "buy" rating on the stock in a report on Tuesday, April 22nd. Three analysts have rated the stock with a hold rating and twenty-two have assigned a buy rating to the stock. Based on data from MarketBeat.com, Neurocrine Biosciences currently has a consensus rating of "Moderate Buy" and a consensus target price of $163.87.

Neurocrine Biosciences Stock Down 0.1%

Shares of Neurocrine Biosciences stock traded down $0.19 on Monday, hitting $131.83. The stock had a trading volume of 470,113 shares, compared to its average volume of 1,146,710. Neurocrine Biosciences, Inc. has a one year low of $84.23 and a one year high of $157.98. The stock has a market cap of $13.05 billion, a price-to-earnings ratio of 44.69, a PEG ratio of 1.35 and a beta of 0.24. The stock's 50-day simple moving average is $126.07 and its two-hundred day simple moving average is $121.21.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its earnings results on Monday, May 5th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by ($0.62). The firm had revenue of $572.60 million during the quarter, compared to the consensus estimate of $587.06 million. Neurocrine Biosciences had a return on equity of 11.81% and a net margin of 12.68%. The firm's revenue for the quarter was up 11.1% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.20 EPS. As a group, equities analysts predict that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Insiders Place Their Bets

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 457 shares of the business's stock in a transaction dated Thursday, July 10th. The stock was sold at an average price of $135.00, for a total transaction of $61,695.00. Following the completion of the sale, the insider directly owned 4,730 shares in the company, valued at $638,550. The trade was a 8.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Jude Onyia sold 59,819 shares of the business's stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $130.46, for a total value of $7,803,986.74. Following the sale, the insider owned 18,289 shares of the company's stock, valued at approximately $2,385,982.94. This represents a 76.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 120,251 shares of company stock worth $14,978,602 in the last 90 days. Corporate insiders own 4.30% of the company's stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.